Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Puma Biotechnology (NASDAQ:PBYI) issued its earnings results on Thursday. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.12, FiscalAI reports. The firm had revenue of $54.48 million for the quarter, compared to the consensus estimate of $51.00 million. Puma Biotechnology had a net margin of 20.38% and a return on equity of 53.15%. Puma Biotechnology updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Puma Biotechnology Stock Performance

Shares of NASDAQ:PBYI traded up $1.09 during midday trading on Friday, hitting $5.99. The company had a trading volume of 2,366,087 shares, compared to its average volume of 490,998. Puma Biotechnology has a 12-month low of $2.32 and a 12-month high of $6.07. The company has a fifty day moving average of $5.02 and a two-hundred day moving average of $4.10. The company has a market cap of $301.72 million, a price-to-earnings ratio of 6.11 and a beta of 1.35. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.73 and a quick ratio of 1.62.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Invesco Ltd. increased its holdings in Puma Biotechnology by 88.9% in the 1st quarter. Invesco Ltd. now owns 37,631 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 17,707 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Puma Biotechnology by 3.8% in the first quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company’s stock worth $254,000 after purchasing an additional 3,117 shares during the period. AQR Capital Management LLC increased its stake in shares of Puma Biotechnology by 366.5% in the first quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 39,641 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Puma Biotechnology during the 1st quarter valued at $66,000. Finally, Geode Capital Management LLC raised its position in shares of Puma Biotechnology by 1.7% during the 2nd quarter. Geode Capital Management LLC now owns 971,674 shares of the biopharmaceutical company’s stock valued at $3,333,000 after purchasing an additional 16,218 shares during the period. 61.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PBYI has been the subject of several research analyst reports. Wall Street Zen downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday. Weiss Ratings downgraded shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Puma Biotechnology has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.